Omega Therapeutics IPO Presentation Deck

In vivo PoC Data in Oncology Program - HCC Inhibition of tumor growth after IV treatment every five days with OEC candidate in HCC orthotopic liver tumor model (Hep3B) % Change in luminescence 30000 20000 10000- 0 Negative control OEC Candidate Sorafinib Ⓒ2021 Omega Therapeutics, Inc. 10 Day 15 W 20 ** Not statistically different % Body Weight Change from Baseline ន 10- Negative control OEC Candidate Sorafenib** Statistically significant vs negative control, t-test p<0.05 Sorafenib administered 50 mg/kg po, once daily Arrows denote dosing days L 10 Day 15 H 20 21

View entire presentation